SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-22-013086
Filing Date
2022-08-10
Accepted
2022-08-10 17:01:41
Documents
70
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q otlk-20220630x10q.htm   iXBRL 10-Q 1492178
2 EX-31.1 otlk-20220630xex31d1.htm EX-31.1 9604
3 EX-31.2 otlk-20220630xex31d2.htm EX-31.2 12100
4 EX-32.1 otlk-20220630xex32d1.htm EX-32.1 9503
  Complete submission text file 0001558370-22-013086.txt   6926513

Data Files

Seq Description Document Type Size
5 EX-101.SCH otlk-20220630.xsd EX-101.SCH 44480
6 EX-101.CAL otlk-20220630_cal.xml EX-101.CAL 50494
7 EX-101.DEF otlk-20220630_def.xml EX-101.DEF 219518
8 EX-101.LAB otlk-20220630_lab.xml EX-101.LAB 376862
9 EX-101.PRE otlk-20220630_pre.xml EX-101.PRE 347295
64 EXTRACTED XBRL INSTANCE DOCUMENT otlk-20220630x10q_htm.xml XML 1305025
Mailing Address 485 ROUTE 1 SOUTH BUILDING F, SUITE 320 ISELIN NJ 08830
Business Address 485 ROUTE 1 SOUTH BUILDING F, SUITE 320 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

IRS No.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 10-Q | Act: 34 | File No.: 001-37759 | Film No.: 221152574
SIC: 2836 Biological Products, (No Diagnostic Substances)